Sharechat Logo

AFT Pharmaceuticals Limited (NZX: AFT) AFT welcomes Australian Federal Court appeal success

Thursday 9th December 2021

Text too small?

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today welcomes the Australian Federal Court’s decision this week to allow its appeal of a comparative advertising judgement brought by Reckitt Benckiser.

The Australian Federal Court has found AFT was justified in making a series of claims in relation to the efficacy of its Maxigesic pain relief tablets in comparison to Ibuprofen alone or paracetamol alone.

Reckitt Benckiser has until 4 January 2022 to file an application for special leave to appeal to the High Court should it so chose. We are therefore unable to make further comment at this time.

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

Please see the link below for details

AFT welcomes Australian Federal Court appeal success

Source: AFT Pharmaceuticals Limited



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

SML - Synlait Milk Limited - Trading Halt of Securities
AIA - Auckland Airport announces board chair changes
AIA - Auckland Airport announces board chair changes
CEN - Tauhara commissioning progress update
FPH initiates voluntary limited recall
March 28th Morning Report
KFL Celebrates 20 Years of Excellence in Investment Mgmt.
SVR - Savor FY24 Earnings Guidance & Change in Banking Partner
NZK - NZ King Salmon Investments Limited FY24 Results
March 27th Morning Report